Study of A-319 for B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called A-319 that targets a protein (CD19) on leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has come back, did not respond to treatment, or still has small signs of cancer after chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have B-cell acute lymphoblastic leukemia that is CD19-positive (a specific marker on the cancer cells).
- Your leukemia either did not respond to treatment, came back within a year, or came back after a stem cell transplant.
- If you had a stem cell transplant, it was at least 6 weeks ago for your own cells or 3 months ago for a donor's cells.
- You have no active infections like HIV or hepatitis B/C, and your liver and kidney function are within acceptable limits.
- You have not had anti-CD19 therapy (like CAR-T) or certain immune drugs (like rituximab) within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
This trial tests a new immune cell therapy (CAR-γδ T cells) that targets a protein called CD19 found on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
Hear when a new Acute Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.